UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2014
ALEXZA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| Delaware |
|
000-51820 |
|
77-0567768 |
| (State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
| Alexza Pharmaceuticals, Inc.
2091 Stierlin Court
Mountain View, California |
|
94043 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (650) 944-7000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 2 — Financial Information
| Item 2.02. |
Results of Operations and Financial Condition. |
On August 7, 2014, Alexza Pharmaceuticals, Inc., a
Delaware corporation, issued a press release reporting financial results for the quarter ended June 30, 2014. The press release is attached hereto as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be
deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Section 9 —
Financial Statements and Exhibits
| Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
| Exhibit
Number |
|
Description |
|
|
| 99.1 |
|
Press Release titled “Alexza Reports 2014 Second Quarter Financial Results” dated August 7, 2014. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ALEXZA PHARMACEUTICALS, INC. |
| Date: August 7, 2014 |
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Thomas B. King |
|
|
|
|
|
|
Thomas B. King President and Chief Executive
Officer |
INDEX TO EXHIBITS
|
|
|
| Exhibit
Number |
|
Description |
|
|
| 99.1 |
|
Press Release titled “Alexza Reports 2014 Second Quarter Financial Results” dated August 7, 2014. |
Exhibit 99.1
NEWS RELEASE - for immediate release
Alexza Reports 2014 Second Quarter Financial Results
Management to Review Results and Provide Business Update
in Conference Call Scheduled Today at 5:00 p.m. Eastern Time
Mountain View, California, August 7, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended
June 30, 2014. The net loss for the second quarter was $6.0 million compared to $0.8 million during the same quarter in 2013. During the three months ended June 30, 2013, Alexza recognized $42.8 million in licensing revenue associated with
the signing of the Company’s License and Supply Agreement with Teva Pharmaceuticals USA, Inc. The net loss for the six months ended June 30, 2014 and 2013 was $16.7 million and $21.5 million, respectively. At June 30, 2014, Alexza had
consolidated cash, cash equivalents, marketable securities and restricted cash of $49.2 million.
“In the second quarter of 2014, we have continued
the transition to a commercial company with Ferrer’s launch of ADASUVE® in Sweden, Norway, Denmark, and Finland, with additional European countries planned for 2014 and 2015,” said
Thomas B. King, President and CEO of Alexza. “We have completed a comprehensive product review process over the past nine months, and are excited about the identification of two new Staccato-based product candidates for development, both
based on our current single-dose platform. AZ-008 is expected to be developed for acute treatment of restless legs syndrome and AZ-009 is expected to be developed for hypomobility in Parkinson’s disease patients.”
King continued, “We are also finishing the final stages of preparation for our first clinical trial of AZ-002 in epilepsy patients, and look forward to
initiating the Phase 2 study in the second half of 2014.”
Alexza Business Updates
| |
• |
|
During the second quarter, Teva and Alexza initiated a clinical study to assess the safety and pharmacokinetics of ADASUVE at doses of 2.5, 5 and 10 mg in adolescents. Teva and Alexza believe that data from this Phase 1
study will provide dosing information for each of their respective follow-on efficacy and safety studies in adolescents, which are planned for the U.S. and EU. Alexza manufactured clinical trial materials for this study. |
| |
• |
|
During the second quarter of 2014, Alexza shipped 27,828 total units of ADASUVE, including 23,031 units to Teva and 4,797 units to Ferrer. |
| |
• |
|
Teva and Ferrer continue to target hospitals treating high volumes of patients experiencing agitation associated with schizophrenia or bipolar disorder. Both companies have dedicated sales and medical science teams that
are responsible for communicating with healthcare professionals in these hospitals about ADASUVE, coordinating reviews of ADASUVE for formulary approval, and educating healthcare professionals about the product. |
| |
• |
|
In April, Ferrer initiated sales of ADASUVE in the Nordic Countries, through a distribution agreement with Medivir AB. Ferrer and its distribution partners now market ADASUVE in eight countries in Europe. Ferrer expects
to continue to launch ADASUVE in additional European countries in 2014 and 2015, with France being the next major EU country targeted. |
| |
• |
|
In May, Alexza hosted an analyst day in New York City, NY. Three U.S. clinicians and three EU clinicians made presentations on the treatment of agitation, the evolution of the practice of medicine and, in the case of
the EU clinicians, clinical experience with ADASUVE. Information regarding these presentations can be obtained from Alexza by contacting Alexza Investor Relations via e-mail at investor.info@alexza.com. |
| |
• |
|
In May, Alexza initiated work to increase the ADASUVE production batch size from 5,000 units to 10,000 units. This work is part of a larger set of longer-term activities focused on increasing manufacturing efficiencies
and attaining overall cost reductions for the unit cost of ADASUVE over time. To date, Alexza has manufactured 25 batches of ADASUVE for the U.S. and EU markets. |
| |
• |
|
During the second quarter, Alexza initiated the ADASUVE PASS (Post-Approval Safety Study) and DUS (Drug Utilization Study) clinical trials in the EU. Both studies are part of the post-approval requirements of the EMA
approval for ADASUVE. Both studies will have 20 to 25 unique sites in 5 to 6 countries in the EU. Target enrollment is 1,500 patients for the PASS study and 1,000 patients for the DUS study. |
| |
• |
|
In June, Dr. Edwin S. Kamemoto was promoted to the newly created position of Senior Vice President, Regulatory Affairs. |
| |
• |
|
In July, Alexza provided an update on its pipeline and new product development efforts. In the second half of 2014, Alexza expects to initiate a Phase 2a study of AZ-002 (Staccato® alprazolam), in epilepsy patients. Additionally, Alexza has identified two new Staccato-based product candidates for development - AZ-008 and AZ-009 - which are planned to incorporate the
active pharmaceutical ingredient ropinirole, a dopamine agonist, into Alexza’s proprietary Staccato system. The Company plans to develop AZ-008 for the acute treatment of restless legs syndrome (RLS) and AZ-009 for hypomobility, or
freezing, during “off periods” in Parkinson’s disease (PD) patients. |
Financial Results - Periods Ended June 30, 2014
and 2013
Alexza recorded revenue of $1.5 million and $3.7 million in the three and six months ended June 30, 2014, respectively, compared to
$43.6 million and $44.4 million in the same periods in 2013, respectively. Revenue in 2014 consisted of $1 million in milestone revenue from Ferrer, a result of the commercial introduction of ADASUVE in Spain, $1.1 million of revenue related to the
amortization of the upfront payments from Ferrer and $1.6 million of product revenue for units of ADASUVE sold to Teva and Ferrer. Revenue in 2013 consisted of $42.8 million of licensing revenues from Teva, $1.5 million of revenue associated with
the amortization of the upfront payment from the Ferrer agreement, and $0.1 million of product revenue for units shipped to Ferrer.
GAAP operating
expenses were $12.8 million and $12.6 million in the quarters ended June 30, 2014 and 2013, respectively, and $23.8 million and $22.9 million for the six months ended June 30, 2014 and 2013, respectively.
Cost of goods sold consists primarily of start-up activities related to commercial manufacturing operations, and, to a lesser extent, manufacture of
commercial product. Alexza is in the early stages of commercialization and, as anticipated, has incurred higher cost per unit costs associated with low production volumes. Alexza expects to continue to incur higher than normal indirect costs until
it gets closer to planned manufacturing capacity. All costs associated with the manufacturing process incurred prior to the first commercial product produced in the second quarter of 2013 were expensed as a component of research and development
expense.
Research and development expenses were $4.0 million and $7.2 million during the three and six months ended
June 30, 2014, respectively, and $4.8 million and $11.0 million in the same periods in 2013, respectively. The decrease in research and development expenses in 2014 as compared to 2013 is primarily due to certain expenses related to
manufacturing, supply chain and quality being classified as cost of goods sold or inventory in 2014.
General and administrative expenses were $3.9
million and $7.9 million during the three and six months ended June 30, 2014 and $4.8 million and $8.9 million in the same periods in 2013, respectively. The decrease was primarily due to a reduction in ADASUVE pre-commercialization efforts
that incurred during the three and six months ended June 30, 2013. Teva assumed responsibilities for these tasks with the license and supply agreement signed in May 2013.
In connection with Alexza’s acquisition of all of the outstanding equity of Symphony Allegro, Inc., or Allegro, in the third quarter of 2009, Alexza is
obligated to pay the former stockholders of Allegro certain percentages of cash receipts that may be generated from future collaboration transactions for ADASUVE, AZ-104 and/or AZ-002. The Company records this obligation as a contingent liability
and updates the liability each quarter. Changes in assumptions underlying the estimate of the fair value of the liability resulted in non-operating, non-cash gains of $7.6 million and $6.4 million during the three and six months ended June 30,
2014, respectively.
In the first half of 2014, Alexza raised net proceeds of approximately $40.8 million through a royalty securitization financing and
drew down the remaining $10.0 million against that certain Convertible Promissory Note and Agreement to Lend, dated as of May 7, 2013, between Alexza and Teva. Alexza believes that with current cash, cash equivalents, marketable securities and
restricted cash balances, estimated product revenues, milestone payments associated with the sale of ADASUVE, and the Company’s current expected cash usage, it has sufficient capital resources to meet its anticipated cash needs, at current cost
levels for at least the next twelve months.
Conference Call Information - 5:00 p.m. Eastern Time on August 7, 2014
To access the webcast via the Internet, go to www.alexza.com, under the “Investor Relations” link. Please log onto the webcast prior to the
start of the call to ensure time for any software downloads that may be required to participate in the webcast.
LIVE CALL:
888-713-4213 or +1-617-213-4865 (international)
Passcode:
23868261
Interested parties may also pre-register for the call at:
https://www.theconferencingservice.com/prereg/key.process?key=P7KJF9AQ7.
REPLAY:
888-286-8010 or +1-617-801-6888 (international)
Passcode: 24951818
A replay of the conference call may also
be accessed at www.alexza.com under the “Investor Relations” link. A replay of the call will be available for 14 days following the event.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous
system conditions. Alexza’s products are based on the Staccato® system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and
therapeutic onset, in a simple, non-invasive manner.
ADASUVE is Alexza’s first commercial product and it has been approved for sale by the U.S. Food
and Drug Administration and the European Commission. Teva Pharmaceuticals USA, Inc. is Alexza’s commercial partner for ADASUVE in the U.S. Grupo Ferrer Internacional S.A. is Alexza’s commercial partner for ADASUVE in Europe, Latin
America and the Commonwealth of Independent States countries.
ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
Alexza’s policy is to provide guidance on product candidates and corporate goals only for the future one to two fiscal quarters, and to provide, update
or reconfirm its guidance only by issuing a press release or filing updated guidance with the SEC in a publicly accessible document. Clinical and corporate milestones guidance is as of August 7, 2014 and financial guidance relating to the
Company’s current cash, cash equivalents, and marketable securities is based upon balances as of June 30, 2014.
This news release
contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company’s expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of
1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and its
partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company’s capital to support the Company’s operations, and
the Company’s ability to raise additional funds and the potential terms of such potential financings. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ
materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2013 and the Company’s other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no
obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
|
|
|
| CONTACT: |
|
Ana Kapor |
|
|
Senior Director, Investor Relations and Corporate Communications |
|
|
650.944.7906 |
|
|
akapor@alexza.com |
ALEXZA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(in thousands, except per share amounts)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended |
|
|
Six Months Ended |
|
| |
|
June 30, |
|
|
June 30, |
|
| |
|
2014 |
|
|
2013 |
|
|
2014 |
|
|
2013 |
|
| Collaboration revenue |
|
$ |
368 |
|
|
$ |
43,529 |
|
|
$ |
2,097 |
|
|
$ |
44,258 |
|
| Product sales |
|
|
1,116 |
|
|
|
106 |
|
|
|
1,553 |
|
|
|
106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total revenue |
|
|
1,484 |
|
|
|
43,635 |
|
|
|
3,650 |
|
|
|
44,364 |
|
|
|
|
|
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of goods sold |
|
|
4,903 |
|
|
|
2,961 |
|
|
|
8,694 |
|
|
|
2,961 |
|
| Research and development |
|
|
4,032 |
|
|
|
4,799 |
|
|
|
7,162 |
|
|
|
11,018 |
|
| General and administrative |
|
|
3,898 |
|
|
|
4,806 |
|
|
|
7,946 |
|
|
|
8,919 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating expenses |
|
|
12,833 |
|
|
|
12,566 |
|
|
|
23,802 |
|
|
|
22,898 |
|
|
|
|
|
|
| Loss from operations |
|
|
(11,349 |
) |
|
|
31,069 |
|
|
|
(20,152 |
) |
|
|
21,466 |
|
|
|
|
|
|
| (Loss)/gain on change in fair value of contingent consideration liability |
|
|
7,599 |
|
|
|
(31,500 |
) |
|
|
6,449 |
|
|
|
(42,400 |
) |
| Interest and other income/ (expense), net |
|
|
2 |
|
|
|
4 |
|
|
|
8 |
|
|
|
17 |
|
| Interest expense |
|
|
(2,214 |
) |
|
|
(372 |
) |
|
|
(3,002 |
) |
|
|
(594 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss |
|
$ |
(5,962 |
) |
|
$ |
(799 |
) |
|
$ |
(16,697 |
) |
|
$ |
(21,511 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic and diluted net loss per share |
|
$ |
(0.34 |
) |
|
$ |
(0.05 |
) |
|
$ |
(0.96 |
) |
|
$ |
(1.34 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALEXZA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
| |
|
June 30, |
|
|
December 31, |
|
| |
|
2014 |
|
|
2013(1) |
|
| ASSETS |
|
|
|
|
|
|
|
|
| Current assets: |
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
$ |
10,517 |
|
|
$ |
17,306 |
|
| Marketable securities |
|
|
33,084 |
|
|
|
8,578 |
|
| Receivables |
|
|
1,018 |
|
|
|
129 |
|
| Inventory |
|
|
3,974 |
|
|
|
3,447 |
|
| Prepaid expenses and other current assets |
|
|
2,913 |
|
|
|
1,453 |
|
|
|
|
|
|
|
|
|
|
| Total current assets |
|
|
51,506 |
|
|
|
30,913 |
|
|
|
|
| Property and equipment, net |
|
|
15,782 |
|
|
|
14,991 |
|
| Restricted cash |
|
|
5,562 |
|
|
|
— |
|
| Other assets |
|
|
3,482 |
|
|
|
1,168 |
|
|
|
|
|
|
|
|
|
|
| Total assets |
|
$ |
76,332 |
|
|
$ |
47,072 |
|
|
|
|
|
|
|
|
|
|
| LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
|
|
| Total current liabilities |
|
|
9,694 |
|
|
|
14,898 |
|
| Total noncurrent liabilities |
|
|
102,997 |
|
|
|
56,149 |
|
| Total stockholders deficit |
|
|
(36,359 |
) |
|
|
(23,975 |
) |
|
|
|
|
|
|
|
|
|
| Total liabilities and stockholders’ equity |
|
$ |
76,332 |
|
|
$ |
47,072 |
|
|
|
|
|
|
|
|
|
|
| (1) |
Derived from the audit financial statements on that date. |